TY1B-DR1 Antibody

What is the DR1 protein and what cellular functions does it perform?

DR1 (Down-regulator of transcription 1) is a 19 kDa protein that functions as a transcriptional repressor. The DR1/DRAP1 heterodimer associates with TATA-binding protein (TBP) to repress both activated and basal transcription of class II genes. This interaction prevents the formation of transcription-competent complexes by inhibiting the association of TFIIA and/or TFIIB with TBP . DR1 can bind to DNA independently and is also a component of the ATAC complex, which possesses histone acetyltransferase activity on histones H3 and H4 . DR1 contains a histone fold motif at the amino terminus, a TBP-binding domain, and a glutamine- and alanine-rich region .

What species reactivity can be expected with commercially available DR1 antibodies?

Most commercially available DR1 antibodies demonstrate cross-reactivity with human, mouse, rat, and monkey (H, M, R, Mk) samples . This cross-reactivity is often due to the high sequence conservation of DR1 across mammalian species. For antibodies where reactivity has not been directly tested, manufacturers typically predict reactivity based on sequence homology . Researchers should verify antibody performance with their specific samples, as sequence homology does not always guarantee functional reactivity .

What are the common applications for DR1 antibodies in research?

DR1 antibodies are primarily used for Western blotting (WB), immunoprecipitation (IP), and immunohistochemistry on paraffin-embedded tissues (IHC-P) . For Western blotting, typical dilutions range from 1:500 to 1:1000, while immunoprecipitation protocols generally recommend 1:50 dilutions . These applications enable researchers to detect endogenous DR1 protein levels, examine protein-protein interactions involving DR1, and visualize DR1 localization in tissue samples .

How should I optimize Western blot protocols when using DR1 antibodies?

When performing Western blot with DR1 antibodies, start with the recommended dilution of 1:1000 (for most commercial antibodies) and adjust as needed based on signal intensity . The expected molecular weight of DR1 is approximately 19 kDa , so ensure your gel separation and transfer conditions are optimized for lower molecular weight proteins. For enhanced chemiluminescence (ECL) detection, standard protocols are effective as demonstrated with cell lysates from HeLa, 293T, Jurkat cells, and human testis tissue at concentrations around 10 μg per lane . Always include positive controls such as HeLa cell lysates, which have been validated to express detectable levels of endogenous DR1 .

What are the key considerations for immunoprecipitation experiments with DR1 antibodies?

For successful immunoprecipitation of DR1, use antibody dilutions of approximately 1:50 as recommended by manufacturers . Consider that DR1 forms a heterodimer with DRAP1 and interacts with TBP, which may affect epitope accessibility . When designing co-immunoprecipitation experiments to study DR1 interactions, gentler lysis conditions may help preserve protein-protein interactions. For investigating phosphorylation-dependent interactions, phosphatase inhibitors should be included in all buffers . Additionally, remember that DR1's functionality can be modulated by phosphorylation, which affects its interaction with TBP , so consider using phospho-specific antibodies when studying these regulatory mechanisms.

How can I validate the specificity of DR1 antibody staining in immunohistochemistry?

To validate DR1 antibody specificity in immunohistochemistry, implement multiple controls including: (1) omission of primary antibody to check for non-specific binding of detection systems, (2) use of isotype control antibodies to identify Fc receptor-mediated or non-specific protein interactions, (3) pre-absorption controls with the immunizing peptide, and (4) comparative staining patterns across multiple DR1 antibodies targeting different epitopes . Verified positive tissue controls include human ovarian carcinoma samples, which have demonstrated specific DR1 staining patterns . For paraffin-embedded tissues (IHC-P), follow manufacturer-recommended antigen retrieval protocols to ensure optimal epitope exposure while preserving tissue morphology.

How can DR1 antibodies be used to investigate transcriptional regulation mechanisms?

To investigate DR1's role in transcriptional regulation, researchers can combine chromatin immunoprecipitation (ChIP) with DR1 antibodies to identify genomic regions where DR1 binds, revealing its direct transcriptional targets. Because DR1 forms a complex with DRAP1 that represses transcription by binding to TBP , sequential ChIP (ChIP-reChIP) can be employed to identify genomic loci where the entire complex assembles. Coupling these approaches with transcriptome analysis (RNA-Seq) in DR1 knockdown/knockout models enables researchers to correlate DR1 binding with gene expression changes . For investigating how phosphorylation affects DR1 function, combine phospho-specific antibodies with mutation studies (such as phosphomimetic mutations) to determine how post-translational modifications alter DR1's interaction with TBP and subsequent transcriptional outcomes .

What strategies can be employed to study DR1's role in protein complexes like the ATAC complex?

To study DR1's involvement in the ATAC complex and other protein assemblies, implement a multi-technique approach beginning with co-immunoprecipitation using DR1 antibodies, followed by mass spectrometry to identify associated proteins . For structural studies, combine this with size-exclusion chromatography to isolate intact complexes. Since DR1 functions within the ATAC complex that has histone acetyltransferase activity , couple DR1 ChIP with histone modification ChIP (sequential ChIP) to correlate DR1 binding with specific histone acetylation patterns. For functional studies, utilize CRISPR/Cas9-mediated mutagenesis to generate DR1 variants that disrupt specific protein interactions while maintaining others, allowing dissection of DR1's distinct roles within different complexes. Blue-native PAGE can also be employed to visualize and isolate intact DR1-containing complexes under non-denaturing conditions.

How can phospho-proteomics approaches be integrated with DR1 antibody studies?

To integrate phospho-proteomics with DR1 antibody studies, implement SILAC (Stable Isotope Labeling with Amino acids in Cell culture) combined with DR1 immunoprecipitation to identify phosphorylation changes in DR1-associated proteins under different experimental conditions . DR1 itself is phosphorylated in vivo, and this phosphorylation affects its interaction with TBP . Use phospho-specific antibodies in combination with general DR1 antibodies to determine the ratio of phosphorylated to total DR1 under various cellular conditions. For comprehensive pathway analysis, couple these approaches with kinase inhibitor screens to identify the regulatory kinases responsible for DR1 phosphorylation. This multi-faceted approach can reveal how signaling cascades regulate DR1 function through post-translational modifications and subsequent alterations in protein-protein interactions .

What are common issues when detecting DR1 by Western blot and how can they be resolved?

When encountering problems detecting DR1 by Western blot, consider that the small size of DR1 (19 kDa) may require optimization of gel percentage (12-15% acrylamide) and transfer conditions . If signal is weak, ensure sample preparation preserves protein integrity by including protease inhibitors and maintaining cold temperatures throughout preparation. For inconsistent results across cell lines, note that DR1 expression levels may vary, with consistent detection reported in HeLa, 293T, and Jurkat cells . Non-specific bands can be addressed by increasing antibody dilution to 1:1000-1:2000, extending wash steps, and optimizing blocking conditions. If phosphorylation status affects antibody recognition, consider treating samples with phosphatase before SDS-PAGE or use phospho-specific antibodies for more nuanced analysis .

How should researchers interpret variations in DR1 protein levels across different experimental models?

When interpreting variations in DR1 protein levels, consider that DR1 functions as a transcriptional repressor , so its abundance may inversely correlate with the expression of its target genes. Analyze DR1 levels in conjunction with its binding partner DRAP1, as their stoichiometry can affect repressive function . Since DR1 represses both activated and basal transcription of class II genes, correlate DR1 abundance with the transcriptional status of known target genes using RT-qPCR or RNA-Seq . Consider that post-translational modifications, particularly phosphorylation, can affect DR1 function without changing total protein levels , so parallel analysis with phospho-specific antibodies may provide additional insights. Finally, evaluate cellular stress conditions, as transcriptional repressors often show altered regulation during stress responses.

What controls should be included when studying DR1 phosphorylation status?

When studying DR1 phosphorylation, include both technical and biological controls. For technical validation, treat a portion of your samples with lambda phosphatase to generate completely dephosphorylated DR1 as a negative control . As positive controls, treat cells with phosphatase inhibitors like okadaic acid to maximize phosphorylation levels. Include samples from different cell cycle stages, as phosphorylation often varies with cell cycle progression. When using phospho-specific antibodies, validate specificity with peptide competition assays using phosphorylated and non-phosphorylated peptides . For biological relevance, correlate phosphorylation changes with functional readouts like alterations in DR1-TBP binding (using co-immunoprecipitation) or changes in transcriptional activity of DR1-regulated genes . Finally, consider generating phosphomimetic (e.g., T143E) and phospho-deficient (e.g., T143A) DR1 mutants to directly test the functional consequences of specific phosphorylation events .

How might DR1 antibodies contribute to understanding the role of DR1 in disease models?

DR1 antibodies can significantly advance the understanding of disease models by enabling precise quantification of DR1 expression and localization changes in pathological tissues. Since DR1 functions as a transcriptional repressor that affects class II gene expression , aberrant DR1 activity could contribute to dysregulated gene expression in cancer and other diseases. Researchers can employ DR1 antibodies in tissue microarray analyses to identify correlations between DR1 expression/localization and disease progression or patient outcomes. Combined with phospho-specific antibodies, this approach can reveal how signaling pathway alterations in disease states affect DR1 phosphorylation and subsequent function . Additionally, DR1 antibodies can facilitate the development of chromatin immunoprecipitation sequencing (ChIP-seq) profiles in normal versus diseased tissues, revealing genome-wide alterations in DR1 binding that may contribute to pathological gene expression programs.

What emerging technologies could enhance the utility of DR1 antibodies in research?

Emerging technologies promise to expand DR1 antibody applications beyond traditional methods. Proximity ligation assays (PLA) could enable in situ visualization of DR1 interactions with partners like DRAP1 and TBP with superior sensitivity and spatial resolution . Mass cytometry (CyTOF) with metal-conjugated DR1 antibodies could allow simultaneous detection of DR1 alongside dozens of other proteins in single cells, revealing complex regulatory relationships. CRISPR epitope tagging combined with endogenous DR1 antibodies could facilitate live-cell imaging of DR1 dynamics during transcriptional responses. Single-molecule pull-down (SiMPull) using DR1 antibodies could reveal the stoichiometry and assembly kinetics of DR1-containing complexes. Finally, integration with spatial transcriptomics could correlate local DR1 protein levels with gene expression patterns in intact tissues, providing unprecedented insights into DR1's region-specific functions in normal and diseased states .